Bildkälla: Stockfoto

Xbrane Biopharma Q2 2024: Initial take – stronger sales but higher costs - Redeye

Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher than estimated. However, the cost base and cash burn also surpassed expectations, resulting in a weaker EBIT than anticipated.

Redeye’s initial take on Xbrane’s Q2 report is that end-customer sales and profit split were higher than estimated. However, the cost base and cash burn also surpassed expectations, resulting in a weaker EBIT than anticipated.
Börsvärldens nyhetsbrev
ANNONSER